CorMedix (CRMD) completed its previously announced acquisition of Melinta Therapeutics, a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses. Acquisition is expected to be highly accretive in 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix Inc. Advances in Infection Prevention with DEFENCATH® Study
- Cormedix Inc. Advances Pediatric Study on DefenCath® for Infection Prevention
- CorMedix Completes $150M Convertible Notes Offering
- CorMedix Inc. Earnings Call Highlights Strategic Growth
- CorMedix price target lowered to $17 from $20 at H.C. Wainwright